FdaApplication
NDA 210884
Identifiers
- fda_app_no: NDA210884
Properties
| Property | Value |
|---|---|
| applicant_name | TONIX MEDICINES INC |
| application_type | NDA |
| approval_date | 2019-01-25 |
Revenue by product
TOSYMRA
| Period | Revenue |
|---|---|
| Q2 2026 | $0.6M |
| Q1 2026 | $0.2M |
| Q4 2025 | $0.8M |
| Q3 2025 | $0.7M |
| Q2 2025 | $0.4M |
| Q1 2025 | $0.4M |
| Q4 2024 | $0.1M |
| Q3 2024 | $0.3M |
| Q2 2024 | $0.5M |
| Q1 2024 | $0.6M |
| Q4 2023 | $0.8M |
| Q3 2023 | $0.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TOSYMRA | SUMATRIPTAN | 10MG/SPRAY | SPRAY;NASAL |
1 product